Bio-Gene Technology Limited (ASX:BGT)
Australia · Delayed Price · Currency is AUD 0.0230
+0.0010 (4.55%)
Aug 5, 2026, 3:06 PM AEST
Bio-Gene Technology Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| - | - | 0.02 | 0.15 | 0.45 | 0.06 | |
Revenue Growth | - | - | -87.72% | -66.52% | 611.91% | -49.01% |
Cost of Revenue | -0.08 | 0.25 | 0.32 | 0.27 | 0.22 | 0.12 |
Gross Profit | 0.08 | -0.25 | -0.3 | -0.12 | 0.22 | -0.06 |
Selling, General & Admin | 1.54 | 1.44 | 1.69 | 1.48 | 1.23 | 0.87 |
Research & Development | 1.93 | 1.38 | 1.07 | 1.98 | 1.9 | 1.68 |
Other Operating Expenses | -0.9 | -0.48 | -0.6 | -0.45 | 0.02 | -0.22 |
Operating Expenses | 2.62 | 2.38 | 2.19 | 3.06 | 3.19 | 2.38 |
Operating Income | -2.54 | -2.62 | -2.5 | -3.18 | -2.97 | -2.43 |
Interest Expense | - | - | - | - | - | -0 |
Interest & Investment Income | 0.02 | 0.04 | 0.09 | 0.09 | 0.05 | 0.04 |
Other Non Operating Income (Expenses) | 0 | 0 | -0 | - | - | - |
EBT Excluding Unusual Items | -2.52 | -2.58 | -2.41 | -3.1 | -2.91 | -2.4 |
Pretax Income | -2.52 | -2.58 | -2.41 | -3.1 | -2.91 | -2.4 |
Net Income | -2.52 | -2.58 | -2.41 | -3.1 | -2.91 | -2.4 |
Net Income to Common | -2.52 | -2.58 | -2.41 | -3.1 | -2.91 | -2.4 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 263 | 211 | 186 | 168 | 153 | 137 |
Shares Outstanding (Diluted) | 263 | 211 | 186 | 168 | 153 | 137 |
Shares Change | 24.58% | 13.68% | 10.76% | 9.41% | 11.73% | 14.96% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | -2.62 | -2.54 | -2.76 | -3.28 | -2 | -1.83 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
Gross Margin | - | - | - | -79.57% | 49.83% | -90.03% |
Operating Margin | - | - | -13625.67% | -2132.08% | -665.67% | -3887.62% |
Profit Margin | - | - | -13150.54% | -2074.48% | -653.81% | -3827.29% |
Free Cash Flow Margin | - | - | -15065.19% | -2195.48% | -448.66% | -2920.54% |
EBITDA | -2.49 | -2.58 | -2.46 | -3.14 | -2.92 | -2.39 |
D&A For EBITDA | 0.04 | 0.04 | 0.04 | 0.05 | 0.04 | 0.04 |
EBIT | -2.54 | -2.62 | -2.5 | -3.18 | -2.97 | -2.43 |
Revenue as Reported | 0.52 | 0.52 | 0.71 | 0.68 | 0.94 | 0.64 |